Grant Zeng, CFA
Research analyst, CFA, biotech, small-cap

When Alnylam Reports ALN-TTR02 Results, Investors Should Look At Tekmira A Second Time

Tekmira: an important upcoming catalyst from ALN-TTR02

While Tekmira (TKMR) is making every effort to advance its own pipeline such as PLK1 and Ebola, investors may forget catalysts from the company's partnered programs. One important upcoming event will be the data release of ALN-TTR02 Phase II trial from partner Alnylam (NASDAQ:ALNY) at the Peripheral Nerve Society Meeting in France on June 30, 2013.

As a reminder, Tekmira has granted a license to Alnylam Pharmaceuticals, Inc. to use Tekmira's lipid nanoparticle (LNP) technology to enable RNAi therapeutic products. Tekmira will receive milestone and royalty payments as these LNP-enabled products are developed and commercialized. ALNY is developing three RNAi therapeutics using Tekmira's LNP technology.

ALN-TTR02

Alnylam has guided that initial

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details